PFIZER INC 8-K

What Happened

• Pfizer filed a Regulation FD disclosure on June 18, 2026 following its announcement of a Chief Financial Officer transition. The company reaffirmed its full‑year 2026 guidance first introduced on December 16, 2025 and reiterated on its Q1 2026 earnings call (May 5, 2026).
• The reaffirmed guidance includes Revenues of $59.5 billion to $62.5 billion and Adjusted Diluted EPS of $2.80 to $3.00. The filing refers readers to Pfizer’s 2026 First Quarter Earnings Release (May 5, 2026) for defined terms and additional detail.

Key Details

• Reaffirmed full‑year 2026 revenue range: $59.5B – $62.5B.
• Reaffirmed full‑year 2026 adjusted diluted EPS range: $2.80 – $3.00.
• Disclosure date: June 18, 2026; guidance originally announced Dec 16, 2025 and reaffirmed May 5, 2026.
• Filing includes standard forward‑looking statements and a detailed list of risk factors; directs investors to the 2025 Form 10‑K and subsequent reports for more risks.

Why It Matters

• For investors, the key takeaway is that Pfizer is maintaining its previously announced 2026 financial outlook despite the announced CFO transition, which preserves management’s revenue and earnings expectations for the year.
• The 8‑K is a Regulation FD disclosure and does not change guidance figures; however, it reiterates that guidance is forward‑looking and subject to many risks (R&D, regulatory, market demand for COVID‑related products, pricing, supply, macroeconomic and geopolitical factors). Investors should consider those risk factors and prior filings when evaluating Pfizer’s outlook.